NCT05471128Active, not recruiting
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy for the Detection of Clinically Significant Prostate Cancer
Source: ClinicalTrials.gov · Last updated 18 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to find out how best to detect clinically significant lesions of prostate cancer by using micro-ultrasound technology (ExactVu) and by multiparametric magnetic-resonance imaging (mpMRI).
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 29 (actual)
- First submitted
- 13 Jul 2022
- Start date
- 27 Jan 2023
- Primary completion date
- 1 May 2025
- Lead sponsor
- University of Oklahoma
- Diseases
- Prostate cancer
- NCT number
- NCT05471128
What you commit to
- Study type: Observational
- Participants enrolled: 29
- From 27 Jan 2023 to the primary completion date, 1 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously confirmed prostate cancer diagnosis with Grade Group \>= 2
- Prostate biopsy within 8 weeks prior to mpMRI.
Other illness
- Any history of prostate treatment
Other
- Unable to undergo prostate biopsy
- Prostate MRI unable to be evaluated using the PI-RADS v2 criteria
- Men with contraindication for MRI or a prostate biopsy
Who the study is looking for
- Patients scheduled to undergo biopsy and with one of the following:
- Men with suspicion of prostate cancer
- Men on active surveillance
- Age ≥18 \[30\]
- Have available multiparametric prostate MRI
- Able to provide written, informed consent
- No significant medical illness which in the opinion of the Investigator would preclude entry to study procedures
- Be willing and able to comply with scheduled visits
Age in the registry: 18 years to 99 years · Sex: Male
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Oklahoma Health Sciences Center, Stephenson Cancer Center Coordinator of this site? Confirm its status | Oklahoma City | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.